

Solution and soluble polymer syntheses of 3-aminoimidazoline-2,4-diones

Juyoung Yoon,[†] Chang-Woo Cho, Hyunsoo Han and Kim D. Janda*


Department of Chemistry, The Scripps Research Institute and The Skaggs Institute for Chemical Biology, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA. E-mail: kjanda@scripps.edu

Received (in Corvallis, OR, USA) 9th September 1998, Accepted 6th November 1998

3-Aminoimidazoline-2,4-dione derivatives have been synthesized from a combination of α - and aza-amino acids by both solution phase and soluble polymer supported approaches; this soluble polymer methodology combines clean product isolation with recycling of the original matrix.

Molecular diversity based on combinatorial organic synthesis is now being used for rapid lead generation in both drug discovery and the development of biologically active compounds with potential therapeutic value.¹ Recently, solid-phase synthesis of heterocycles bearing one or more nitrogen atoms such as diketopiperazines,² diazines,³ and hydantoins⁴ has received considerable attention due to their medicinal importance. Hence, development of strategies for the mixture/parallel synthesis of additional heterocyclic structures either in solution or on a polymer support is of key interest.


The synthesis and structure assignment of hexahydro-1,2,4-triazine-3,6-dione **2**, isomeric with 3-aminoimidazoline-2,4-dione **1**, has been rather cryptic for over 30 years.^{5–7} It has been demonstrated^{6,7} that a hexahydro-1,2,4-triazine-3,6-dione could be prepared by the reaction of *N*-[*N*-(phenylthiocarbonyl)glycyl]-*N'*-(benzyloxycarbonyl)hydrazine with lead acetate.⁸ A similar cyclization of ethyl semicarbazinoacetate [$\text{H}_2\text{NNHC(O)NHCH}_2\text{CO}_2\text{Et}$] with NaOEt⁹ was discovered to lead to **1** rather than **2**. A more recent attempt¹⁰ to synthesize 1,2,4-triazine-3,6-diones by the reaction of hydrazine with α -lactams gave mainly **1**.¹¹ If **1** or **2** could be made in a controlled



fashion they should make interesting targets for combinatorial synthesis/drug discovery as they are structurally rigid, possess ample hydrogen donor/acceptor functionality and contain two points for diversity generation. Herein we describe our synthetic approach to 3-aminoimidazoline-2,4-diones **1**, our application of this strategy to a soluble polymer support, and our ability to design a methodology that allows regeneration of the resin.

As detailed *vide supra* examples relating to the controlled syntheses of 3-aminoimidazoline-2,4-dione derivatives have been sparse. In 1985, a concise one step synthesis from α -amino acids and *tert*-butyl carbazate was reported by Lalezari,¹² however, this report also detailed a major problem with this synthetic tack which induced racemization of the product. To avoid this unwanted racemization, our solution phase approach utilized Et₃N or Pr₂NH at room temperature for the cyclization step, allowing optical activity[‡] to be preserved.

As shown in Scheme 1, *N*-benzyloxycarbonyl protected amino acids were used as convenient starting materials in the solution phase synthesis. Thus, protected amino acids were coupled with our previously described Boc-protected aza-amino acids¹³ using DCC and DMAP in typically 95% yield.




Scheme 1 Reagents and conditions: i, DCC, DMAP; ii, H₂/Pd-C; iii, **7** (1.1 equiv.), Et₃N (1.1 equiv.); iv, TFA–CH₂Cl₂ (1:1 v/v); v, dilution, Et₃N (1.1 equiv.).

After removal of the benzyloxycarbonyl (Z) group, nitrophenyl chloroformate was introduced to generate an activated intermediate for the cyclization reaction. Removal of the Boc group was performed using TFA–CH₂Cl₂ (1:1), followed by cyclization in Et₃N–CH₂Cl₂ (1:100 v/v) at 25 °C, and the desired unracemized 3-aminoimidazoline-2,4-diones **9** were obtained in approximately 75% yield.

With a sound solution phase strategy in hand we extended our methodology to a soluble polymer supported synthesis. In this scenario linear homopolymer [polyethylene glycol monomethyl ether (MeO-PEG)] served as our carrier for polymer synthesis and purification. We have demonstrated the advantages of using liquid phase synthesis through the construction of both peptide/small molecule combinatorial libraries¹⁴ and as a reagent/catalyst support.¹⁵

Linker **10** was prepared *via* the oxidation of 4-(*tert*-butoxy)benzaldehyde with Ag₂O. This acid was coupled to MeO-PEG5000-amine and upon deprotection with TFA gave phenol **11** which was now ready for the first diversity step coupling (Scheme 2). The amino acid was introduced in the form of isocyanate **12**¹⁶ and this building block was attached to **11** granting **13**; the second point of diversity, Boc-aza-amino acid **4** was added to deprotected **13** providing PEG-**14**. It should be stressed that the unique physical properties of the MeO-PEG homopolymer allowed each coupling/deprotection reaction to be purified by precipitation of the modified homopolymer. Furthermore, reaction progress was conveniently monitored by ¹H and ¹³C NMR spectroscopy. Finally, after removal of the Boc group, **14** could be base-cyclized and thus cleaved from the support generating a variety of 3-aminoimidazoline-2,4-diones in greater than 90% purity and in 62–80% yield (Table 1). The structures of the products were confirmed by ¹H, ¹³C NMR and FAB mass as well as IR spectroscopy. § For example, ¹H NMR analysis of **9d** in [2H₆]DMSO clearly shows a doublet at δ 2.49 for NCH₃ and a quartet for NH at δ 5.43. Also, all of the compounds showed distinct peaks in their IR spectra at 1775 and 1725 cm⁻¹ which is indicative of a 3-aminoimidazoline-2,4-dione structure.⁵ Lastly, it was possible to regenerate PEG-**11** and reapply this material in another round of synthesis. This was accomplished by simple treatment of the isolated reaction PEG-**11** with 1 M NaOH which in effect removed any previous

[†] Present address: Department of Chemistry, Silla University, 1-1 San, Kwabop-dong, Sasang-gu, Pusan, 617-736 Korea.



Scheme 2 Reagents and conditions: i, MeO-PEG-CH₂CH₂NH₂, DCC, DMAP; ii, TFA-CH₂Cl₂ (1:1 v/v); iii, **12**, Et₃N; iv, **4**, DCC; v, dilution, Pr₂NEt (1.1 equiv.), vi, 1 M NaOH.

Table 1 3-Aminoimidazoline-2,4-diones generated via Scheme 2

Compound	R ¹	R ²	Yield (%) ^a
9a	H	Me	62
9b	Me	Me	73
9c	Pr ⁱ	Me	75
9d	Bu ^s	Me	78
9e	Bn	Me	80
9f	Bn	<i>p</i> -MeOC ₆ H ₄ CH ₂	78
9g	Bn	Bu ⁱ	74
9h	Me	H	60
9j	Bu ⁱ	H	67
9k	Bn	H	67

^a Yields are based on the conversion of **11** to **9** and are isolated yields.

materials that had accumulated during the synthesis of **9**. We could use this PEG-**11** again without any significant reduction in loading or yield, which was confirmed by ¹H NMR analysis.

In conclusion, we have shown both solution and liquid phase methodologies for the controlled stepwise synthesis of 3-aminoimidazoline-2,4-diones. In our strategy we have provided a method that allows for the incorporation of two points of diversity which can be drawn from a large pool of building blocks. Finally, our approach allows for polymer regeneration and its reuse.

Financial support of this research by the Skaggs Institute for Chemical Biology and NIH GM56154 is gratefully acknowledged. C.-W. C. wishes to thank Korea Science and Engineering Foundation (KOSEF) for a postdoctoral fellowship. We also thank Professor R. V. Hoffman for many helpful discussions.

Notes and references

‡ Optical rotation values for **9b,c,e–g,j** are reported in their characterization data (see below). In the case of **9b**, there was no significant change in its optical rotation value after a first and second recrystallization from EtOH.

This supports our assumption that there was no sign of racemization in our synthetic scheme. {before recrystallization: $[\alpha]_D^{24} -39.0$ (c 1.06, MeOH), after first recrystallization: $[\alpha]_D^{24} -38.8$ (c 1.06, MeOH), after second recrystallization: $[\alpha]_D^{24} -40.3$ (c 1.04, MeOH)}

§ Selected data for **9a**: mp 189–191 °C; δ_H ([²H₆]DMSO, 400 MHz) 8.00 (br s, 1H), 5.40 (br s, 1H), 3.87 (d, 2H), 2.51 (d, 3H); δ_C ([²H₆]DMSO, 101 MHz) 169.8, 156.5, 44.5, 36.9; ν (CHCl₃)/cm⁻¹ 3024, 1772, 1724, 1211; HRMS [FAB, (M + 1)⁺]: calc. 130.0617, found 130.1612. For **9b**: mp 182–185 °C; δ_H (CD₃OD, 400 MHz) 3.99 (q, 1H), 2.55 (s, 3H), 1.27 (d, 3H); δ_C (CD₃OD, 101 MHz) 172.5, 155.1, 50.1, 34.9, 14.8; ν (CHCl₃)/cm⁻¹ 3006, 1768, 1724, 1214; HRMS [FAB, (M + 1)⁺]: calc. 144.0773, found 144.0766; $[\alpha]_D^{24} -39.0$ (c 1.06, MeOH). For **9c**: mp 138–140 °C; δ_H (CDCl₃, 400 MHz) 6.73 (br s, 1H), 4.32 (br s, 1H), 3.90 (d, 1H), 2.72 (s, 3H), 2.23 (m, 1H), 1.04 (d, 3H), 0.91 (d, 3H); δ_C (CDCl₃, 101 MHz) 171.3, 156.9, 60.9, 38.0, 30.2, 18.6, 15.9; ν (CHCl₃)/cm⁻¹ 3024, 1774, 1718, 1208; HRMS [FAB, (M + Na)⁺]: calc. 194.0905, found 194.0914; $[\alpha]_D^{24} -73.0$ (c 0.69, CHCl₃). For **9d**: δ_H (DMSO, 400 MHz) 8.17 (s, 1H), 5.53 (q, 1H), 3.97 (d, 1H), 2.49 (d, 3H), 1.77 (m, 1H), 1.18–1.34 (m, 2H), 0.90 (d, 3H), 0.84 (t, 3H); δ_C (CD₃OD, 101 MHz) 169.6, 154.2, 57.3, 34.3, 33.6, 20.8, 11.2, 8.0; ν (CHCl₃)/cm⁻¹ 3024, 2986, 1774, 1718, 1214; HRMS [FAB, (M+1)⁺]: calc. 186.1242, found 186.1239. For **9e**: mp 210–213 °C; δ_H (CDCl₃, 400 MHz) 7.30 (m, 5H), 5.45 (br s, 1H), 4.26 (q, 1H), 4.23 (m, 1H), 3.28 (dd, 1H), 2.90 (dd, 1H), 2.58 (d, 3H); δ_C (CDCl₃, 101 MHz) 170.6, 155.5, 134.6, 129.4, 128.9, 127.6, 61.0, 56.9, 37.8; ν (CHCl₃)/cm⁻¹ 3011, 1762, 1724, 1227; HRMS [FAB, (M + 1)⁺]: calc. 220.1086, found 220.1094; $[\alpha]_D^{24} -63.9$ (c 0.39, MeOH). For **9f**: mp 125–128 °C; δ_H (CDCl₃, 400 MHz) 7.30 (m, 5H), 7.16 (d, 2H), 6.86 (d, 2H), 5.24 (s, 1H), 4.35 (br s, 1H), 4.15 (m, 1H), 3.95 (d, 2H), 3.78 (s, 3H), 3.23 (dd, 1H), 2.69 (dd, 1H); δ_C (CDCl₃, 101 MHz) 170.6, 159.4, 155.6, 134.9, 130.7, 129.3, 128.9, 127.7, 127.5, 113.8, 56.9, 55.2, 53.9, 37.8; ν (CHCl₃)/cm⁻¹ 3011, 1755, 1737, 1215; HRMS [FAB, (M + Na)⁺]: calc. 348.1324, found 348.1335; $[\alpha]_D^{24} -76.0$ (c 0.42, MeOH). For **9g**: δ_H (CDCl₃, 400 MHz) 7.28 (m, 5H), 6.21 (s, 1H), 4.26 (q, 1H), 4.21 (m, 1H), 3.21 (dd, 1H), 2.94 (dd, 1H), 2.53 (t, 2H), 1.55 (m, 1H), 0.90 (d, 3H); δ_C (CDCl₃, 101 MHz) 170.9, 156.1, 134.5, 129.5, 128.8, 127.5, 58.4, 56.8, 37.5, 26.6, 20.3; ν (CHCl₃)/cm⁻¹ 3440, 3023, 1774, 1731, 1214; HRMS [FAB, (M+H)⁺]: calc. 262.1556, found 262.1563; $[\alpha]_D^{24} -66.7$ (c 0.59, MeOH). For **9h**: mp 134–136 °C; δ_H (CD₃OD, 400 MHz) 3.99 (q, 1H), 1.26 (d, 3H); δ_C (CD₃OD, 101 MHz) 173.1, 156, 50.1 14.9; ν (CHCl₃)/cm⁻¹ 3021, 1784, 1726, 1208; HRMS [FAB, (M + 1)⁺]: calc. 130.0616, found 130.0612. For **9i**: mp 150–153 °C; δ_H (CD₃OD, 400 MHz) 3.95 (m, 1H), 1.71 (m, 1H), 1.54 (m, 1H), 1.39 (m, 1H), 0.84 (d, 6H); δ_C (CD₃OD, 101 MHz) 171.3, 154.7, 51.3, 37.9, 21.6, 19.4, 17.1; ν (CHCl₃)/cm⁻¹ 3023, 1793, 1724, 1208; HRMS [FAB, (M + 1)⁺]: calc. 172.1086, found 172.1080; $[\alpha]_D^{24} -78.1$ (c 0.64, MeOH). For **9k**: mp 201–203 °C; δ_H (CD₃OD, 400 MHz) 7.16 (m, 5H), 4.23 (m, 1H), 3.03 (dd, 1H), 2.89 (dd, 1H); HRMS [FAB, (M + 1)⁺]: calc. 206.0930, found 206.0924.

- 1 *Molecular Diversity and Combinatorial Chemistry*, ed. I. M. Chaiken and K. D. Janda, American Chemical Society, Washington DC, 1996; L. A. Thompson and J. A. Ellman, *Chem. Rev.*, 1996, **96**, 555; M. A. Gallop, R. W. Barrett, W. J. Dower, S. P. A. Fodor and E. M. Gordon, *J. Med. Chem.*, 1994, **37**, 1233.
- 2 A. K. Szardenings, T. S. Burkoth, H. H. Lu, D. W. Tien and D. A. Campbell, *Tetrahedron*, 1997, **53**, 6573; D. W. Gordon, J. Steele, *Bioorg. Med. Chem. Lett.*, 1995, **5**, 47.
- 3 J. S. Panek and B. Zhu, *Tetrahedron Lett.*, 1996, **37**, 8151.
- 4 J. Matthews and R. A. Rivero, *J. Org. Chem.*, 1997, **62**, 6090; S. W. Kim, S. Y. Ahn, J. S. Koh, J. H. Lee, S. Ro and H. Y. Cho, *Tetrahedron Lett.*, 1997, **38**, 460.
- 5 J. Gut, A. Novoccek and P. Fiedler, *Collect. Czech. Chem. Commun.*, 1968, **33**, 2087.
- 6 J. G. Dain, Doctoral Dissertation, Duquesne University, 1970, *Diss. Abstr. Int. B*, 1971, **32**, 160; *Chem. Abstr.*, 1972, **76**, 3807.
- 7 T. J. Schwan and T. J. Sanford, *J. Heterocycl. Chem.*, 1979, **16**, 1655.
- 8 A. Lindemann, N. H. Khan and K. Hoffman, *J. Am. Chem. Soc.*, 1952, **74**, 476.
- 9 J. Gante and W. Lautsch, *Chem. Ber.*, 1964, **97**, 994.
- 10 R. V. Hoffman and N. K. Nayyar, *J. Org. Chem.*, 1995, **60**, 5992.
- 11 Professor R.V. Hoffman, Personal communication.
- 12 I. Lalezari, *J. Heterocycl. Chem.*, 1985, **22**, 741.
- 13 H. Han and K. D. Janda, *J. Am. Chem. Soc.*, 1996, **118**, 2539.
- 14 D. J. Gravert and K. D. Janda, *Chem. Rev.*, 1997, **97**, 489.
- 15 P. Wentworth Jr., A. M. Vandersteen and K. D. Janda, *Chem Commun.*, 1997, 759; H. Han and K. D. Janda, *Angew. Chem., Int. Ed. Engl.*, 1997, **36**, 1731; H. Han and K. D. Janda, *J. Am. Chem. Soc.*, 1996, **118**, 7632; H. Han and K. D. Janda, *Tetrahedron Lett.*, 1997, **38**, 1527.
- 16 Isocyanates **12** were prepared from *tert*-butyl amino acids and triphosgene. See S. Goldschmidt and M. Wick, *Liebigs Ann. Chem.*, 1952, **575**, 217 for this preparation.

Communication 8/070671